MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
MDM2 and MDMX, negative regulators of the tumor suppressor p53, can work separately and as a heteromeric complex to restrain p53's functions. MDM2 also has pro-oncogenic roles in cells, tissues, and animals that are independent of p53. There is less information available about p53-independent roles of MDMX or the MDM2–MDMX complex. We found that MDM2 and MDMX facilitate ferroptosis in cells with or without p53. Using small molecules, RNA interference reagents, and mutant forms of MDMX, we found that MDM2 and MDMX, likely working in part as a complex, normally facilitate ferroptotic death. We observed that MDM2 and MDMX alter the lipid profile of cells to favor ferroptosis. Inhibition of MDM2 or MDMX leads to increased levels of FSP1 protein and a consequent increase in the levels of coenzyme Q 10, an endogenous lipophilic antioxidant. This suggests that MDM2 and MDMX normally prevent cells from mounting an adequate defense against lipid peroxidation and thereby promote ferroptosis. Moreover, we found that PPARα activity is essential for MDM2 and MDMX to promote ferroptosis, suggesting that the MDM2–MDMX complex regulates lipids through altering PPARα activity. These findings reveal the complexity of cellular responses to MDM2 and MDMX and suggest that MDM2–MDMX inhibition might be useful for preventing degenerative diseases involving ferroptosis. Furthermore, they suggest that MDM2/MDMX amplification may predict sensitivity of some cancers to ferroptosis inducers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Self-citationFerroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695 · cited 20×
“We therefore suggest that MDM2 and MDMX may also be able to mediate the role of p53 in ferroptosis perhaps in different ways that are specific to particular classes of FINs.”
BackgroundInfluentialSelf-citationIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice
Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3064 · Cited by 3,732
Self-citationThe CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
Bersuker, K., Hendricks, J. M., Li, Z., Magtanong, L., Ford, B., Tang, P. H., Roberts, M. A., Tong, B., Maimone, T. J., Zoncu, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1705-2 · Cited by 3,703
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398 · cited 1×
“Given that mounting evidence suggests that ferroptosis is a tumor-suppressive mechanism (Jiang et al. 2015; Jennis et al. 2016; Murphy 2016; Ou et al. 2016; Wang et al. 2016; Zhang et al. 2019), our data provide a new hypothesis for the field to explore.”
BackgroundFSP1 is a glutathione-independent ferroptosis suppressor
Doll, S., Freitas, F. P., Shah, R., Aldrovandi, M., da Silva, M. C., Ingold, I., Goya Grocin, A., Xavier da Silva, T. N., Panzilius, E., Scheel, C. H., et al. (2019) · Nature · doi:10.1038/s41586-019-1707-0 · Cited by 3,341
Self-citationFerroptosis: Death by Lipid Peroxidation
Yang, W. S., & Stockwell, B. R. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.014 · Cited by 3,088
Self-citationKoves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens, R., Dyck, J. R. B., Newgard, C. B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.013 · Cited by 1,990
GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling
Kraft, V. A. N., Bezjian, C. T., Pfeiffer, S., Ringelstetter, L., Müller, C., Zandkarimi, F., Merl-Pham, J., Bao, X., Anastasov, N., Kössl, J., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.9b01063 · Cited by 1,298
Self-citationMDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · cited 2×
“Mouse models (Wade et al. 2013) have shown that the two proteins have functions that can be both independent of, and dependent on, each other, based on context (Bielskienė et al. 2015; Karni-Schmidt et al. 2016).”
BackgroundExogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State
Magtanong, L., Ko, P.-J., To, M., Cao, J. Y., Forcina, G. C., Tarangelo, A., Ward, C. C., Cho, K., Patti, G. J., Nomura, D. K., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.016 · Cited by 1,147
Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models
Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K., Rosenberg, P. A., Lo, D. C., Weinberg, J. M., Linkermann, A., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411006a · Cited by 1,146 · cited 1×
“Since fer-1 can suppress ferroptotic death in thismodel (Skouta et al. 2014), weused it as a positive control to rescue the death of these MSNs with mutant HTT.”
BackgroundSelf-citationTyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis
Shimada, K., Skouta, R., Kaplan, A., Yang, W. S., Hayano, M., Dixon, S. J., Brown, L. M., Valenzuela, C. A., Wolpaw, A. J., & Stockwell, B. R. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2079 · Cited by 1,017
Self-citationThe Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity
Xie, Y., Zhu, S., Song, X., Sun, X., Fan, Y., Liu, J., Zhong, M., Yuan, H., Zhang, L., Billiar, T. R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.055 · Cited by 952 · cited 1×
“Furthermore, through its protein–protein interaction with DPP4 that controls membrane lipid peroxidation (Xie et al. 2017), p53 can inhibit ferroptosis.”
BackgroundActivation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses
Ou, Y., Wang, S.-J., Li, D., Chu, B., & Gu, W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607152113 · Cited by 765
Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid–Induced AKI
Martin-Sanchez, D., Ruiz-Andres, O., Poveda, J., Carrasco, S., Cannata-Ortiz, P., Sanchez-Niño, M. D., Ruiz Ortega, M., Egido, J., Linkermann, A., Ortiz, A., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121376 · Cited by 564 · cited 2×
“Since there is mounting evidence that ferroptosis mediates kidney injury (Martin-Sanchez et al. 2017) and failure (FriedmannAngeli et al. 2014;Müller et al. 2017), our data provide additional support for the notion thatMDM2 (and MDMX) antagonists might have potential in treating kidney dysfunction.”
Backgroundp53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells
Tarangelo, A., Magtanong, L., Bieging-Rolett, K. T., Li, Y., Ye, J., Attardi, L. D., & Dixon, S. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.077 · Cited by 554
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
Wang, S.-P., Wang, W.-L., Chang, Y.-L., Wu, C.-T., Chao, Y.-C., Kao, S.-H., Yuan, A., Lin, C.-W., Yang, S.-C., Chan, W.-K., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1875 · Cited by 493 · cited 1×
“Furthermore, this protein has roles in cellular metabolism (Riscal et al. 2016), EMT and metastasis (Wang et al. 2009; Chen et al. 2013; Lu et al. 2016; Chen et al. 2017a), cell survival and growth (Feeley et al. 2017), as well as mitochondrial dynamics (Arena et al. 2018).”
BackgroundSorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
Lachaier, E., Louandre, C., Godin, C., Saidak, Z., Baert, M., Diouf, M., Chauffert, B., & Galmiche, A. (2014) · PubMed · Cited by 477
Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms
Belmokhtar, C. A., Hillion, J., & Ségal-Bendirdjian, E. (2001) · Oncogene · doi:10.1038/sj.onc.1204436 · Cited by 474
Acetylation Is Crucial for p53-Mediated Ferroptosis and Tumor Suppression
Wang, S.-J., Li, D., Ou, Y., Jiang, L., Chen, Y., Zhao, Y., & Gu, W. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.022 · Cited by 462
Miess, H., Dankworth, B., Gouw, A. M., Rosenfeldt, M., Schmitz, W., Jiang, M., Saunders, B., Howell, M., Downward, J., Felsher, D. W., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0315-z · Cited by 361 · cited 1×
“Additionally, whenwe blocked β-oxidation using etomoxir, which did indeed increase ferroptotic sensitivity as previously reported (Miess et al. 2018), there was no effect on the ability of MDM2/X antagonists to suppress ferroptosis (Supplemental Fig.”
BackgroundNecroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure
Müller, T., Dewitz, C., Schmitz, J., Schröder, A. S., Bräsen, J. H., Stockwell, B. R., Murphy, J. M., Kunzendorf, U., & Krautwald, S. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2547-4 · Cited by 357
Self-citationJennis, M., Kung, C.-P., Basu, S., Budina-Kolomets, A., Leu, J. I.-J., Khaku, S., Scott, J. P., Cai, K. Q., Campbell, M. R., Porter, D. K., et al. (2016) · Genes & Development · doi:10.1101/gad.275891.115 · Cited by 352
The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344 · cited 2×
“MDM2 has also been found to have tumor suppressor functions in addition to its oncogenic function (Manfredi 2010).”
BackgroundThe Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
Self-citationp21WAF1 and tumourigenesis: 20 years after
Warfel, N. A., & El-Deiry, W. S. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b639e · Cited by 286
Aron, A. T., Loehr, M. O., Bogena, J., & Chang, C. J. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08016 · Cited by 270
Self-citationvan Raalte, D. H., Li, M., Pritchard, P. H., & Wasan, K. M. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041444.06122.8d · Cited by 269
Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators
Gervois, P., Torra, I. P., Fruchart, J.-C., & Staels, B. (2000) · cclm · doi:10.1515/cclm.2000.002 · Cited by 249
p53-Mdm2--the affair that never ends
Alarcon-Vargas, D. (2002) · Carcinogenesis · doi:10.1093/carcin/23.4.541 · Cited by 233
Song, S., Attia, R. R., Connaughton, S., Niesen, M. I., Ness, G. C., Elam, M. B., Hori, R. T., Cook, G. A., & Park, E. A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.05.019 · Cited by 215
Shi, K., Gao, Z., Shi, T.-Q., Song, P., Ren, L.-J., Huang, H., & Ji, X.-J. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00793 · Cited by 204
Poyurovsky, M. V., Priest, C., Kentsis, A., Borden, K. L., Pan, Z., Pavletich, N., & Prives, C. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601465 · Cited by 203 · cited 1×
“The MDM2–MDMX heterodimeric complex forms both through interactions between their respective RING domains (Leslie and Zhang 2016) and through short sequences at their respective C termini (Poyurovsky et al. 2007; Uldrijan et al. 2007).”
BackgroundThe p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193 · cited 1×
“S4H; Uldrijan et al. 2007; Huang et al. 2011).”
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3
Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189 · cited 1×
“Consistentwith previous reports (Patton et al. 2006; Wade et al. 2006; Xia et al. 2008), the levels of MDMX were markedly reduced upon nutlin treatment in the parental HT-1080 cells (Fig.”
ResultImpaired β-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD
Afshinnia, F., Rajendiran, T. M., Soni, T., Byun, J., Wernisch, S., Sas, K. M., Hawkins, J., Bellovich, K., Gipson, D., Michailidis, G., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017030350 · Cited by 183
An essential function of the extreme C-terminus of MDM2 can be provided by MDMX
Uldrijan, S., Pannekoek, W., & Vousden, K. H. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601469 · Cited by 170
Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity
Conklin, K. A. (2005) · Integrative Cancer Therapies · doi:10.1177/1534735405276191 · Cited by 165
Hdmx modulates the outcome of p53 activation in human tumor cells
Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163
Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
Kersten, S. (2008) · PPAR Research · doi:10.1155/2008/132960 · Cited by 149
Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53
Riscal, R., Schrepfer, E., Arena, G., Cissé, M. Y., Bellvert, F., Heuillet, M., Rambow, F., Bonneil, É., Sabourdy, F., Vincent, C., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.033 · Cited by 149
(2003) · PubMed · Cited by 147
Reisz, J. A., Zheng, C., D’Alessandro, A., & Nemkov, T. G. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9236-2_8 · Cited by 146
Self-citationLarraufie, M.-H., Yang, W. S., Jiang, E., Thomas, A. G., Slusher, B. S., & Stockwell, B. R. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.018 · Cited by 136
Self-citationAuwerx, J. H., Schoonjans, K., Fruchart, J., & Staels, B. (1996) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.3.81 · Cited by 120
Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53
Arena, G., Cissé, M. Y., Pyrdziak, S., Châtre, L., Riscal, R., Fuentes, M., Arnold, J. J., Kastner, M., Gayte, L., Bertrand‐Gaday, C., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.01.023 · Cited by 115
Fåhræus, R., & Olivares‐Illana, V. (2013) · Oncogene · doi:10.1038/onc.2013.410 · Cited by 114
Mulay, S. R., Thomasová, D., Ryu, M., & Anders, H. (2012) · Kidney International · doi:10.1038/ki.2011.482 · Cited by 114
Small molecule-induced oxidation of protein disulfide isomerase is neuroprotective
Kaplan, A., Gaschler, M. M., Dunn, D. E., Colligan, R., Brown, L. M., Palmer, A. G., Lo, D. C., & Stockwell, B. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500439112 · Cited by 110
Self-citationMDM2 promotes epithelial–mesenchymal transition and metastasis of ovarian cancer SKOV3 cells
Chen, Y., Wang, D., Wu, Y., Su, D., Zhou, T., Gai, R., Fu, Y., Zheng, L., He, Q., Zhu, H., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.265 · Cited by 107
Cell cycle regulatory functions of the human oncoprotein MDM2.
Deb, S. P. (2003) · PubMed · Cited by 104
p53-Independent Effects of Mdm2
Bohlman, S., & Manfredi, J. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_13 · Cited by 103
Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay
Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C., & Stockwell, B. R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0104 · Cited by 100
Self-citationBAP1 suppresses tumor development by inducing ferroptosis upon SLC7A11 repression
Zhang, Y., Zhuang, L., & Gan, B. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1536845 · Cited by 97
Mdmx and Mdm2: Brothers in Arms?
Marine, J.-C., & Jochemsen, A. G. (2004) · Cell Cycle · doi:10.4161/cc.3.7.998 · Cited by 77
Xia, M., Knezevic, D., Tovar, C., Huang, B., Heimbrook, D. C., & Vassilev, L. T. (2008) · Cell Cycle · doi:10.4161/cc.7.11.5929 · Cited by 75
E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma
Bielskienė, K., Bagdonienė, L., Mozūraitienė, J., Kazbarienė, B., & Janulionis, E. (2015) · Medicina · doi:10.1016/j.medici.2015.01.007 · Cited by 74
Deben, C., Wouters, A., de Beeck, K. O., van Den Bossche, J., Jacobs, J., Zwaenepoel, K., Peeters, M., Van Meerbeeck, J., Lardon, F., Rolfo, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4433 · Cited by 73 · cited 2×
“…been extensive efforts to develop nutlin-like compounds to treat cancers with wild-type p53 (Warner et al. 2012; Atatreh et al. 2018); one possible approach is to pair such compoundswith other chemotherapeutics to achieve a more profound cancer control (Deben et al. 2015; Zanjirband et al. 2016).”
BackgroundThe Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 72
Mdmx promotes genomic instability independent of p53 and Mdm2
Carrillo, A. M., Bouska, A., Arrate, M. P., & Eischen, C. M. (2015) · Oncogene · doi:10.1038/onc.2014.27 · Cited by 69 · cited 1×
“MDMX can enhance tumor progression in some cases by promoting cancer cell growth and genomic instability (Kadakia et al. 2002; Carrillo et al. 2015; Xiong et al. 2017).”
BackgroundChen, Y., Wang, Y., Huang, Y., Zeng, H., Hu, B., Guan, L., Zhang, H., Yu, A., Johnson, C. H., Gonzalez, F. J., et al. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx023 · Cited by 69
Zanjirband, M., Edmondson, R. J., & Lunec, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9499 · Cited by 63
Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells
Feeley, K. P., Adams, C. M., Mitra, R., & Eischen, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0809 · Cited by 63
Mdm2 and MdmX as Regulators of Gene Expression
Biderman, L., Manley, J. L., & Prives, C. L. (2012) · Genes & Cancer · doi:10.1177/1947601912455331 · Cited by 62
Self-citationMatijasevic, Z., Steinman, H. A., Hoover, K., & Jones, S. N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01108-07 · Cited by 58 · cited 2×
“Intriguingly, in some settings MDMXmay have tumorsuppressive roles in limiting cell transformation (Matijasevic et al. 2008) and tumor progression (Mancini et al. 2017), as well as promoting genome stability (Matijasevic et al. 2016).”
BackgroundWang, H., & Yan, C. (2011) · Neoplasia · doi:10.1593/neo.11438 · Cited by 58
Mungamuri, S. K., Qiao, R. F., Yao, S., Manfredi, J. J., Gu, W., & Aaronson, S. A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.049 · Cited by 54 · cited 2×
“2012; Jain and Barton 2016), heterochromatin rearrangement (Mungamuri et al. 2016; Wienken et al. 2017), DNA repair, and replication (Melo and Eischen 2012; Eischen 2017).”
BackgroundPilot screening programme for small molecule activators of p53
Berkson, R. G., Hollick, J. J., Westwood, N. J., Woods, J. A., Lane, D. P., & Lain, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.20968 · Cited by 52
Ironing out how p53 regulates ferroptosis
Murphy, M. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615159113 · Cited by 51
Function and dysfunction of the human oncoprotein MDM2
Deb, S. P. (2002) · Frontiers in bioscience · doi:10.2741/a723 · Cited by 50
Wienken, M., Moll, U. M., & Dobbelstein, M. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw046 · Cited by 49
Chen, X., Qiu, J., Yang, D., Lu, J., Yan, C., Zha, X., & Yin, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078794 · Cited by 47 · cited 2×
“2016), EMT and metastasis (Wang et al. 2009; Chen et al. 2013; Lu et al. 2016; Chen et al. 2017a), cell survival and growth (Feeley et al.”
BackgroundRole of Mdm2 and Mdmx in DNA repair
Eischen, C. M. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw052 · Cited by 45
Quartararo, C. E., Reznik, E., deCarvalho, A. C., Mikkelsen, T., & Stockwell, B. R. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00128 · Cited by 43
Self-citationIdentification of FDA‐approved Drugs that Computationally Bind to MDM2
Warner, W. A., Sanchez, R., Dawoodian, A., Li, E., & Momand, J. A. (2012) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2012.01428.x · Cited by 39
MdmX inhibits Smad transactivation
Kadakia, M., Brown, T. L., McGorry, M. M., & Berberich, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205993 · Cited by 39
Reinhart, P. H., Kaltenbach, L. S., Essrich, C., Dunn, D., Eudailey, J., DeMarco, C. T., Turmel, G. J., Whaley, J. C., Wood, A., Cho, S., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.017 · Cited by 39
Self-citationAtatreh, N., Ghattas, M. A., Bardaweel, S. K., Rawashdah, S. A., & Sorkhy, M. A. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s182444 · Cited by 36
Lu, X., Yan, C., Huang, Y., Shi, D.-M., Fu, Z., Qiu, J., & Yin, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9287 · Cited by 35
Regulation of Peroxisome Proliferator–Activated Receptor-α by MDM2
Gopinathan, L., Hannon, D. B., Peters, J. M., & Heuvel, J. P. V. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn260 · Cited by 33
The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis
Xiong, S., Pant, V., Zhang, Y., Aryal, N. K., You, M. J., Kusewitt, D. F., & Lozano, G. (2016) · The Journal of Pathology · doi:10.1002/path.4854 · Cited by 33
XI-006 induces potent p53-independent apoptosis in Ewing sarcoma
Pishas, K. I., Adwal, A., Neuhaus, S. J., Clayer, M., Farshid, G., Staudacher, A. H., & Callen, D. F. (2015) · Scientific Reports · doi:10.1038/srep11465 · Cited by 27
Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery
Ye, L. F., Reznik, E., Korn, J. M., Lin, F., Yang, G., Malesky, K., Gao, H., Loo, A. T., Pagliarini, R. A., Mikkelsen, T., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27457 · Cited by 22
Self-citationProtecting the genome from mdm2 and mdmx
Melo, A. N., & Eischen, C. M. (2012) · Genes & Cancer · doi:10.1177/1947601912454139 · Cited by 20
MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability
Mancini, F., Teveroni, E., Conza, G. D., Monteleone, V., Arisi, I., Pellegrino, M., Buttarelli, M., Pieroni, L., D’Onofrio, M., Urbani, A., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0626-7 · Cited by 20
MDM2 oligomers: antagonizers of the guardian of the genome
Leslie, P. L., & Zhang, Y. (2016) · Oncogene · doi:10.1038/onc.2016.88 · Cited by 19
Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
Kon, N., Wang, D., Li, T., Jiang, L., Qiang, L., & Gu, W. (2018) · Oncotarget · doi:10.18632/oncotarget.23837 · Cited by 17
Matijašević, Z., Krzywicka-Racka, A., Sluder, G., Gallant, J., & Jones, S. N. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.62 · Cited by 14
Outside the p53 RING: Transcription Regulation by Chromatin-Bound MDM2
Jain, A. K., & Barton, M. C. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.035 · Cited by 5
Cited by
Ferroptosis: mechanisms, biology and role in disease
Jiang, X., Stockwell, B. R., & Conrad, M. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00324-8 · Cited by 7,505
Self-citationFerroptosis: molecular mechanisms and health implications
Tang, D., Chen, X., Kang, R., & Kroemer, G. (2021) · Cell Research · doi:10.1038/s41422-020-00441-1 · Cited by 4,256
Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications
Stockwell, B. R. (2022) · Cell · doi:10.1016/j.cell.2022.06.003 · Cited by 3,056
Self-citationBroadening horizons: the role of ferroptosis in cancer
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 2,897
The Cell Biology of Ferroptosis
Dixon, S. J., & Olzmann, J. A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00703-5 · Cited by 1,596
Metadata
- Authors
- Venkatesh, D., O'Brien, N. A., Zandkarimi, F., Tong, D. R., Stokes, M. E., Dunn, D. E., Kengmana, E. S., Aron, A. T., Klein, A. M., Csuka, J. M., Moon, S.-H., Conrad, M., Chang, C. J., Lo, D. C., D'Alessandro, A., Prives, C., & Stockwell, B. R.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2020-02-20
- Volume
- 34
- Issue
- 7-8
- Pages
- 526-543
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W3008915658
- Cited by
- 274
- References
- 92
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.